Epilepsy and Driving
Epilepsy can lead to cognitive impairments, particularly in attention, which may affect daily activities such as driving. Driving plays a key role in maintaining autonomy and is essential for the social and professional integration of people with epilepsy. Therefore, assessing fitness to drive is a major issue for indi
| Condition(s) | Epilepsy |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Epilepsy can lead to cognitive impairments, particularly in attention, which may affect daily activities such as driving. Driving plays a key role in maintaining autonomy and is essential for the social and professional integration of people with epilepsy. Therefore, assessing fitness to drive is a major issue for individuals with epilepsy. French legislation governing driving for people with epilepsy clearly outlines the periods during which a person is not permitted to drive. However, the means or methods for evaluating driving fitness in these individuals are not well defined. Currently, assessment is based more on a medical consultation than on a comprehensive evaluation of driving ability. Using a driving simulator in combination with an EEG could be a valuable approach to better asse |
| Who can participate | Inclusion Criteria * Aged between 18 and 65 years * Holder of a category B driving license * Active driver: drives at least once a month * No medical condition contraindicating driving, except for epilepsy * Provides explicit consent to participate in the study * Affiliated with or a beneficiary of a social security scheme Exclusion Criteria: * Subject to legal protection (guardianship and curatorship are accepted for individuals with epilepsy, as this population represents a significant proportion of our institution's patients) * Pregnant or breastfeeding women * Known cybersickness (virtual reality or simulator sickness) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Locations | Tain-l'Hermitage, France |
| Start date | 2025-11-06 |
| NCT ID | NCT07026591 |
| Official listing | https://clinicaltrials.gov/study/NCT07026591 |